A recent study found positive associations between the organic matter component of particulate matter and disease aggravation in amyotrophic lateral sclerosis (ALS).
A study published in Environmental Epidemiology found that fine particulate matter (PM2.5) composition could have a direct effect on amyotrophic lateral sclerosis (ALS), with organic matter (OM) having a significant association with disease aggravation. The aim of the study was to assess whether year-long exposures to relatively medium to low concentrations of PM2.5 differ in their association with ALS aggravation.
The study used data from the New York Department of Health Statewide Planning and Research Cooperative System, in which patients with ALS were identified between 2000 and 2014 by checking hospital discharge records for their first ALS hospitalization. The data set also held information on age, sex, and residential address to properly assess county-level exposure.
Annual PM2.5 black carbon, nitrate, sulfate, OM, sea salt, and soil mass concentrations were predicted by an air pollution prediction model. The total mass of PM2.5 in 1 area was estimated from satellite retrievals. Investigators predicted the annual concentrations in a county subdivision, then calculated an overall county average that weighted the county subdivisions with larger populations more heavily.
In 62 New York state counties, there was an annual mean (SD) of 6.0 (9.6) first ALS hospitalizations per county, with 5655 first ALS hospitalizations from 2000 to 2014. The mean age at first hospitalization was 64.3 (13.5) years.
OM and sulfate had the highest mean mass concentrations in the state, with 35% and 31% of total PM2.5 mass, respectively, whereas sea salt had the lowest with 3% of total PM2.5 mass. Sulfate and soil concentrations in the air had a downward pattern over time; OM, nitrate, and sea salt also decreased gradually over time.
The researchers found that a 1-SD increase in OM concentration was associated with a 17% (rate ratio [RR], 1.17; 95% CI, 1.11-1.24) increase in the annual ALS first hospitalization rate and a 1-SD increase in sea salt with a 6% increase (RR, 1.06; 95% CI, 1.01-1.11). There was an inverse correlation between soil (RR, 0.91; 95% CI, 0.86-0.97) or black carbon (RR, 0.94; 95% CI, 0.89-0.99) and first hospitalization for ALS.
There were some limitations to this study. Because the data included only information on hospitalizations, the investigators lacked any data on noncases that would allow an individual-level time-to-event analysis. The analysis was limited to the county level. The study used predicted PM2.5 exposure rather than measured exposure, and some exposure measurement error is expected. A county-wide average may not reflect population exposure for components adequately. The PM2.5 components in this study do not encompass all possible components.
OM’s total particulate mass was analyzed, but OM is a mixture and includes multiple chemical compounds. First hospitalization data are also likely to miss aggravation if patients are not hospitalized as disease symptoms worsen.
The researchers concluded that there were positive associations of some PM2.5 chemical components with ALS, with a specific association between OM and disease aggravation in ALS.
“This information can be useful in identifying relevant pollution sources for targeted regulations and in studies of PM2.5 toxicity and ALS pathology,” the authors wrote.
References
Nunez Y, Boehme AK, Goldsmith J, et al. PM2.5 composition and disease aggravation in amyotrophic lateral sclerosis. Environ Epidemiol. 2022;6:e204. doi:10.1097/EE90000000000000204
Muscle-Directed Therapy Apitegromab Meets Primary End Point in Phase 3 SAPPHIRE Trial of SMA
October 17th 2024Patients aged 2-21 receiving apitegromab showed clinically meaningful motor function improvements, with a favorable safety profile consistent with long-term data, as Scholar Rock prepares for US and EU regulatory submissions in Q1 2025.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
New Research Unearths Evidence of Global Metabolic Disruption in Patients With SMA
September 21st 2024A recent analysis investigated the state of metabolic disruption experienced by patients with spinal muscular atrophy (SMA), adding to the literature on nutritional and metabolic complications linked to SMA.
Read More